OH
VIRX

Oikos Holdings’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Oikos Holdings’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,211
Closed -$365K – 4
2018
Q3 		$365K Hold
5,211
– – 0.31% 8
2018
Q2 		$387K Hold
5,211
– – 0.24% 10
2018
Q1 		$496K Hold
5,211
– – 0.39% 9
2017
Q4 		$673K Buy
+5,211
New +$488K 0.39% 9

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Oikos Holdings's VIRX Position: Q4 2018 in Review

Oikos Holdings sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2018, closing a stake of 5,211 shares — an estimated $365K sold.

Oikos Holdings first reported a position in VIRX in Q4 2017 and held it in 4 quarters. The position peaked at $673K in Q4 2017. 40 funds tracked by Wall St. Rank hold VIRX as of Q4 2018.

  • Oikos Holdings reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Oikos Holdings sold 5,211 Viracta Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $365K.
  • Oikos Holdings first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 4 quarters.
  • Oikos Holdings's Viracta Therapeutics, Inc. Common Stock position peaked at $673K in Q4 2017.
  • 40 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Oikos Holdings's 13F filing for Q4 2018, filed 11 Feb 2019.